HIPK4 accelerates cutaneous squamous cell carcinoma progression by phosphorylating TAp63 and inhibiting EFEMP1
Ze Guo1, Bingjie Chen1, Mengya Zhang1
1Department of Dermatology, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, P.R. China.
Abstract:
Cutaneous squamous cell carcinoma (CSCC) is a common skin cancer with a tendency to metastasize, leading to poor patient prognosis. Homeodomain interacting protein kinase 4 (HIPK4) has been identified as a key inhibitor of human skin epithelial differentiation. However, the role of HIPK4 in regulating CSCC development remains unclear. Our preliminary experiment showed that HIPK4 was highly expressed in CSCC tumor tissues and cells. In this study, we investigate the role of HIPK4 in regulating CSCC progression and the underlying mechanisms. In the current study, the interaction between HIPK4 and TAp63 was analyzed by Co-IP and GST-pull down assays, and the relationship between TAp63 and EFEMP1 was analyzed by ChIP and dual luciferase reporter assays. Our results showed that EFEMP1 expression was decreased in CSCC tissues and cells, and EFEMP1 overexpression inhibited CSCC cell proliferation, migration, and invasion. In addition, HIPK4 was upregulated in CSCC; knocking down HIPK4 suppressed CSCC cell malignant behaviors and tumor growth in mice. Mechanistically, HIPK4 promoted tumor progression by phosphorylating the tumor suppressor TAp63 at Ser395, leading to decreased expression of EFEMP1, a key extracellular matrix protein with anti-tumor properties. As expected, the inhibitory effects of HIPK4 knockdown on CSCC cell malignant behaviors were reversed by EFEMP1 knockdown. In summary, HIPK4 could exacerbate CSCC malignant progression by inhibiting EFEMP1 through phosphorylating TAp63, highlighting HIPK4 as a potential therapeutic target in CSCC. Our results provide new insights into the molecular mechanisms underlying CSCC progression and propose novel strategies for therapeutic intervention.
Insights
Homeodomain interacting protein kinase 4 (HIPK4) drives cutaneous squamous cell carcinoma (CSCC) progression by inhibiting EFEMP1 via TAp63 phosphorylation. Targeting HIPK4 may offer a new therapeutic strategy for CSCC.
Area of Science:
- Oncology
- Molecular Biology
- Dermatology
Background:
- Cutaneous squamous cell carcinoma (CSCC) is a prevalent skin cancer with metastatic potential.
- Homeodomain interacting protein kinase 4 (HIPK4) inhibits skin epithelial differentiation, but its role in CSCC is unknown.
- HIPK4 is upregulated in CSCC tissues, suggesting a role in tumorigenesis.
Purpose of the Study:
- To investigate the role of HIPK4 in CSCC progression.
- To elucidate the molecular mechanisms by which HIPK4 regulates CSCC.
- To evaluate HIPK4 as a potential therapeutic target for CSCC.
Main Methods:
- Co-immunoprecipitation (Co-IP) and GST-pull down assays to analyze protein interactions.
- Chromatin immunoprecipitation (ChIP) and dual luciferase reporter assays to study gene regulation.
- In vitro assays for cell proliferation, migration, and invasion; in vivo tumor growth studies in mice.
Main Results:
- EFEMP1 expression is decreased in CSCC; its overexpression suppresses CSCC cell malignancy.
- HIPK4 is upregulated in CSCC and its knockdown inhibits tumor growth and malignant behaviors.
- HIPK4 phosphorylates TAp63, decreasing EFEMP1 expression and promoting CSCC progression.
Conclusions:
- HIPK4 promotes CSCC progression by inhibiting EFEMP1 through TAp63 phosphorylation.
- HIPK4 is a potential therapeutic target for cutaneous squamous cell carcinoma.
- This study provides insights into CSCC molecular mechanisms and therapeutic strategies.
Related Concept Videos
MAPK Signaling Cascades
PI3K/mTOR/AKT Signaling Pathway
Renewal of Skin Epidermal Stem Cells
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal


